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Summary. Congenital factor XIII (FXIII) deficiency
is an extremely rare, yet potentially life-threatening,
bleeding disorder, with a 30% rate of spontaneous
intracranial haemorrhage. Routine prophylactic
management is recommended for all individuals with
clinically relevant (FXIII) deficiency and for all
symptomatic individuals with congenital factor defi-
ciency. Fibrogammin P is a purified, pasteurized
concentrate of FXIII that appears to carry negligible
risk of viral transmission, unlike other unprocessed
products containing FXIII. An ongoing Phase II/III
study of Fibrogammin P in patients with congenital
FXIII deficiency is being conducted to evaluate the
prophylactic efficacy and long-term safety of this
product. Using retrospective chart review data from
subjects enrolled in the Phase II/III study, the current
analysis was designed to compare spontaneous bleed-
event rates prior to and after the initiation of
Fibrogammin P prophylaxis. Seven subjects were
evaluable for comparison, having received no other
prophylactic FXIII-containing product during the
24 months prior to study entry. The mean annual
number of spontaneous bleeds was 2.5 events per
year prior to Fibrogammin P prophylaxis and
0.2 events per year during Fibrogammin P prophy-
laxis (P = 0.01). Patients reported no severe bleeds
during Fibrogammin P therapy. This small sample
supports a consistent and clinically meaningful
reduction in spontaneous bleeding with prophylactic
use of Fibrogammin P.
Keywords: blood coagulation factors, factor XIII,
factor XIII deficiency, genetics, prophylaxis, retro-
spective studies
Introduction
Congenital deficiency of factor XIII (FXIII, fibrin
stabilizing factor) is an extremely rare, but severe and
potentially life-threatening hereditary bleeding dis-
order [1]. The estimated incidence is approximately
one affected person per million population [2–5].
Factor XIII deficiency was first clinically identified in
1960 in a child born of a consanguineous marriage
[2,6]. Genetic inheritance is autosomal recessive in
nature, and a higher incidence of compound hetero-
zygosity is observed among non-consanguineous
families [5].
Delayed umbilical haemorrhage is a presenting
feature in 80)90% of FXIII deficiency cases and
should arouse strong suspicion for the disorder [1].
Standard coagulation tests (prothrombin time, par-
tial thromboplastin time) are usually normal for age.
Specialized testing, including a clot solubility and
FXIII activity assay, are required to make an accurate
diagnosis [1]. Factor XIII deficiency is also charac-
terized by a particularly high frequency of potentially
fatal intracranial haemorrhage (30% of cases),
often occurring spontaneously or following very
minor trauma [7]. This feature alone makes FXIII
deficiency one of the most serious bleeding disorders.
It also provides a basis for widely accepted recom-
mendations that all patients with clinically relevant
deficiency receive routine FXIII replacement therapy
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[1,6]. These patients also have a life-long propensity
for subcutaneous bleeding into the skin, subcutane-
ous tissues, muscles, and joints. In the absence of
effective treatment, most patients with FXIII defi-
ciency continue to manifest repeated and prolonged
bleeding episodes leading to various degrees of
debilitation and potentially death [8]. Recently
published questionnaire data from the International
Registry on Factor XIII Deficiency reflect the expe-
riences of 104 patients worldwide and confirm high
rates of subcutaneous (57%), umbilical cord (56%),
muscle (49%), joint (36%), and central nervous
system (34%) bleeds among individuals with this
deficiency [8]. While the majority of persons with
FXIII deficiency are severely affected, the specific
alterations of the FXIII protein show a high degree of
heterogeneity and clinical manifestations can be
highly variable from patient to patient [2]. As a
consequence, individual bleeding patterns, tenden-
cies, and severity will differ among affected patients
[8,9]. The extent of bleeding inversely correlates with
patients’ FXIII level. For example, patients who
experience only mild bleeding have a low mean FXIII
level of 0.9 ± 0.6% of normal, whereas patients with
severe bleeding have a much higher mean FXIII level
of 4.6 ± 16.7% of normal [9].
The greatest risk of severe spontaneous bleeding
occurs when FXIII levels are below 1 U dL)1, and
routine replacement therapy with FXIII concentrate
is recommended for such patients from the time of
diagnosis. Individuals with FXIII levels between 1
and 4 U dL)1 are still prone to moderate to severe
bleeding, and FXIII replacement therapy should also
be strongly considered [2].
Unlike most coagulation factors, FXIII has a long
circulating half-life (7–12 days) and full haemostatic
activity even at low concentrations, making it par-
ticularly suitable for routine prophylactic replace-
ment [10]. In the past, replacement had been
achieved using fresh-frozen plasma (FFP) or cryo-
precipitate. However, the usefulness of these prod-
ucts for lifelong prophylaxis is hindered by the
potential risk of hepatitis and other blood-borne
diseases.
Fibrogammin P (CSL Behring GmbH, Marburg,
Germany) is a purified concentrate of FXIII obtained
from HIV-negative, pooled human plasma screened
for common viruses. The manufacturing process
includes rigorous viral inactivation and elimination
techniques, including pasteurization at 60C for
10 h, adsorption of AL(OH)3/Vitacel and defibrini-
zation, as well as ion exchange chromatography,
making viral disease transmission highly unlikely.
This high margin of safety is supported by the
absence of any proven cases of virus transmission
due to Fibrogammin P administration during clin-
ical trials or reported via postmarketing surveillance.
Due to its long half-life (7–12 days), Fibrogammin
P can be conveniently administered for prophylactic
treatment once every 3)4 weeks. Scheduled monthly
treatment with 10–30 units kg)1 of Fibrogammin P
is considered sufficient in most cases to maintain
FXIII levels above a critical threshold to prevent
bleeding episodes [2,11]. It is provided in lyophilized
vials containing 250 units or 1 250 units, and is
reconstituted with Sterile Water for Injection USP.
Fibrogammin P is licensed in several countries in
Asia, Europe, and South American, but not in the
United States.
An ongoing investigational new drug (IND) study
is evaluating the prophylactic efficacy and long-term
safety of Fibrogammin P [11]. The study is cur-
rently being conducted at 39 sites in the United States
and has enrolled 61 subjects, who are thought to
represent approximately two-thirds of US patients
with FXIII deficiency based on incidence. Response
to therapy has been good to excellent in these
patients, who have been followed for up to 9 years,
with no inhibitor development and no seroconver-
sions. No major intracranial or life-threatening
bleeds have been reported in patients on study while
receiving continual prophylaxis.
Due to the high rate of spontaneous intracranial
haemorrhage, there is no control group in the
prophylaxis follow-up study. Therefore, to generate
a meaningful ‘control’ data set, historical records of
bleeding events were reviewed for some study sub-
jects and used to compare bleed frequencies prior to
and during Fibrogammin P prophylaxis. Adequate
historical data were not available for all subjects
because of early diagnosis or other factors. The
findings for seven eligible patients are nonetheless of
clinical value in relation to managing this rare
disorder.
Materials and methods
This was a retrospective, chart review analysis of
selected participants in an ongoing Phase II/III study
(hereafter, ‘main study’) of Fibrogammin P prophy-
laxis. An overview of the methodology for this main
study is being provided as relevant background
information.
Methodology of main study
Any patient with congenital FXIII deficiency was
eligible to enrol in the main study, including children
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and newborns. Individuals with acquired FXIII
deficiency were not eligible. A total of 61 patients
have been enrolled at 37 study sites. An FXIII
pharmacokinetic analysis was performed in each
subject following a 4-week washout period (no FXIII
or other blood-product infusion), preferably prior to
the first Fibrogammin P infusion. The first dose of
Fibrogammin P for pharmacokinetic analysis was
20 U kg)1 given over a 5-min period. The circulating
half-life of FXIII was determined for each subject
(data to be reported elsewhere) and used to calculate
an individualized dosing regimen to maintain FXIII
levels within a protective range. Patients continued to
receive Fibrogammin P infusions at 3)4 week
intervals. Further descriptions of the study method-
ology, as well as some preliminary findings, have
been published elsewhere [11].
Methodology for historical control analysis of
bleeding frequency
When the mean length of treatment with Fibrogam-
min P in the main study was 22 months, patients’
medical records were retrospectively reviewed for the
24 months prior to study entry to generate an
historical comparison database. The criteria for
gathering useful historical control data excluded
many of the subjects enrolled in the main study.
First, data collection was limited to subjects from
study sites that had enrolled two or more subjects.
Second, subjects could not have received routine
prophylactic infusions of cryoprecipitate, FFP, or
FXIII from any other sources during the historical
review period. Finally, historical data was sought for
a 24-month period prior to the start of Fibrogam-
min P prophylaxis. For some patients, especially
very young children, the interval between FXIII
deficiency diagnosis (or date of birth) and start of
Fibrogammin P prophylaxis was often less than
6 months, rendering many subjects ineligible for
retrospective comparison.
The number of bleeding episodes was recorded for
each subject before and during Fibrogammin P
prophylaxis. Bleeding frequency per year was calcu-
lated for each subject. Mean bleeding frequencies
before and during Fibrogammin P prophylaxis were
compared using a two sided paired t-test with
a = 0.05.
Results
Thirteen patients at four study sites were eligible for
chart review for historical and on-treatment bleeding
data. Subjects ranged between the ages of 10 months
and 29 years. Of the 13 cases reviewed, two had
incomplete historical information (medical records
inaccessible or missing the required data). Four
additional subjects had received prophylactic treat-
ment with cryoprecipitate or FFP during the
24 months prior to starting Fibrogammin P pro-
phylaxis and were also excluded from the current
analysis. The remaining seven patients had received
no prior prophylaxis with FXIII or other blood
products during the historical assessment period,
allowing a true comparison of bleeding frequency
with and without Fibrogammin P prophylaxis.
Table 1 provides a summary of dosing and bleed-
ing-episode data for these subjects prior to study
entry (pre-Fibrogammin P therapy) and while
receiving Fibrogammin P prophylaxis. Patients
were dosed on a unit basis. Variability in weight
and vial size led to a range of doses per kilogram.
The annual spontaneous bleeding rates in evalu-
able subjects decreased during Fibrogammin P
prophylaxis (Fig. 1). The majority of subjects (six
of seven, 86%) had experienced one or more
bleeding episodes during the historical assessment
period. Five of the seven subjects (71%) experienced
no spontaneous bleeding while receiving Fibrogam-
min P therapy. The two bleeding episodes recorded
in subject 3302 while on Fibrogammin P prophy-
laxis were related to normal postpartum events, and
as such, were not considered spontaneous bleeds or
ineffectiveness of the prophylactic treatment. Disre-
garding these events, the mean number of spontane-
ous bleeds during Fibrogammin P therapy was 0.2
per year, significantly less than the mean calculated
for the prestudy interval (2.5 events per year;
P = 0.01).
One severe bleeding event (intracranial bleed,
subject 3 303) was documented during the
24 months prior to starting Fibrogammin P pro-
phylaxis. No intracranial bleeds or other severe
bleeding events were observed during Fibrogammin
P administration.
Case summaries
Subject 504 was a male subject born in February
1998 and diagnosed with FXIII deficiency in Sep-
tember 2003 (FXIII level at diagnosis <10%). During
the 24-month period prior to entering the Fibrogam-
min P study in September 2003, this subject
experienced two abnormal bleeding episodes: a
haematoma on the right thigh and one involving
the rib cage, neither of which required treatment. No
bleeding events were recorded during 12 months of
Fibrogammin P prophylaxis.
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Subject 2703 was a 10-month-old female at the
time of study enrollment. She had experienced an
umbilical cord bleed approximately 2 weeks after
birth in December 1999 and was treated with FFP
and vitamin K, and was diagnosed with FXIII
deficiency (categorized as ‘severe’). She was enrolled
in the Fibrogammin P prophylaxis study in Sep-
tember 2000, and only one spontaneous bleed was
recorded during 25 months of treatment.
Subject 2704 was diagnosed with severe FXIII
deficiency in February 2000 following increased
bleeding after circumcision (no treatment given).
Three additional bleeding episodes occurred prior to
enrollment in the Fibrogammin P study in August
2000: bleeding gums/bruise on forehead, frenulum
bleed, and a forehead haematoma, all of which were
treated with FFP. Two bleeding events occurred in
this subject over 26 months of Fibrogammin P
prophylaxis: one on the foot and one on the head.
Subject 2705 was a male patient born in 1994 and
diagnosed with severe FXIII deficiency in 2002.
During a surgery (umbilical hernia repair) in 1999,
he had experienced increased bleeding, hypovola-
emia, and anaemia and was given two units of
packed red blood cells. Following diagnosis, this
subject began Fibrogammin P prophylaxis in Jan-
uary 2005. During the prior 24 months, three
bleeding episodes had been recorded: lower lip, right
ankle injury, and a forehead haematoma, all treated
with FFP. No bleeding episodes occurred during
13 months of Fibrogammin P prophylaxis.
Subject 3301 was a male patient enrolled in the
Fibrogammin P study at 19 years of age (June
2001). At the time of diagnosis in 1986, his FXIII
level was <1%. During the 24 months prior to
Fibrogammin P prophylaxis, he experienced five
spontaneous bleeding episodes characterized as hae-
































































































































































































































































































































































































































































































































































































































































































Fig. 1. Calculated rates of spontaneous bleeding (events per year)
for previously un-prophylaxed subjects, prior to and during
Fibrogammin P prophylaxis. Annual rates were extrapolated
where necessary.
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bruise on the forehead, all treated with FFP. During
Fibrogammin P prophylaxis in the main study,
there were no spontaneous bleeds during 9.5 months
(11 Fibrogammin P doses) of observation.
Subject 3302 was diagnosed with FXIII deficiency
(FXIII levels <1%) shortly after birth in 1983. Her
history included four bleeding events requiring
administration of FFP. Her historical assessment
period was evaluated as the 24 months prior to
February 1990, during which time she had no
significant bleeding episodes. While enrolled in the
Fibrogammin P prophylaxis study, she experienced
two episodes of normal postpartum bleeding.
Subject 3303, a 14-year-old male subject (FXIII
levels <1%), started Fibrogammin P prophylaxis in
March 1990. During his 24-month historical assess-
ment period, he was noted to have had eight
spontaneous bleeding episodes: three episodes of
bleeding gums, treated with aminocaproic acid
(Amicar or FFP); two forehead haematomas (one
treated with FFP, one not treated); an intracranial
bleed treated with FFP every 3 days while hospital-
ized; bleeding following a MediPort placement,
treated with FFP; and a haematoma on the thigh,
treated with FFP. No spontaneous bleeding events
were evident during 10 months (11 infusions) of
Fibrogammin P prophylaxis.
Discussion and conclusion
This review of historical bleed data in patients with
congenital FXIII deficiency before and during Fibro-
gammin P therapy provides a ‘control’ data per-
spective in a population for which traditional
placebo-controlled protocols are problematic. There
were no set parameters for follow-up interval, and
this review was simply intended to provide a soft
‘snapshot’ of experience before and during Fibro-
gammin P prophylaxis. The follow-up intervals are
not indicative of discontinuation of therapy or
patients being lost to follow-up. The results demon-
strate a consistent and clinically meaningful reduc-
tion in spontaneous bleeding from mild trauma with
prophylactic use of Fibrogammin P from a mean of
2.5 episodes per year to 0.2 episodes per year com-
pared to no treatment in a small group of patients
with symptomatic congenital FXIII deficiency.
Although retrospectively gathered data formed the
basis for this analysis, the on-treatment data were
obtained as part of a carefully supervised prospective
clinical trial; likewise, historical records of prior
bleeding events were expected to be well-docu-
mented, considering the nature of the disorder and
the management of these subjects at Hemophilia
Treatment Centers. Ongoing findings from the larger
IND study of Fibrogammin P in congenital FXIII
deficiency should continue to produce more rigorous
scientific outcomes, especially as patient accrual
continues. To date, no serious adverse events have
been reported.
The first prospective study of Fibrogammin P was
carried out in France and involved 19 patients from
15 centers [12]. Sixteen patients were given regular
prophylaxis with Fibrogammin P ranging from 19
to 108 weeks without major bleeds. Response was
defined as good to excellent, and no patients devel-
oped detectable antibodies. Published case report
series have reported similar efficacy [1,13].
Fibrogammin P is currently marketed in a num-
ber of countries, including Japan, Germany, and the
United Kingdom. Marketing approval in the United
States is being pursued. A new recombinant FXIII-A2
product is also under investigation, one that involves
no human or mammalian production elements.
Preliminary research supports indications that it
may be an effective alternative, although longer-term
studies will be required to confirm immunogenicity
risk and overall safety [14].
Other products have been used for the treatment of
FXIII deficiency, including FFP and cryoprecipitate,
although the limited data regarding prophylactic use
in this population suggest efficacy inferior to expe-
rience with Fibrogammin P. Garcia-Talavera et al.
described the bleeding and treatment patterns of
seven patients with FXIII deficiency from four
families in Tenerife, Spain, over a 30-year period.
Prior to 1983, six patients received FFP
(250)500 mL every 4 weeks) prophylactic therapy
[15]. Bleeding events reported during this period
included four episodes of central nervous system
bleeding, a newborn death, and a fatal bleeding
diathesis related to high-titre inhibitor. Two patients
also developed chronic VHC infection. Three
patients have received prophylaxis with Fibrogam-
min P (every 4 weeks) since 1983. Throughout an
average observation period of 171 months, there
were no reports of bleeding episodes in patients using
prophylactic Fibrogammin P, and one woman
experienced an uncomplicated pregnancy using the
product every 3 weeks. In addition, both FFP and
cryoprecipitate carry potential risks of blood-borne
disease transmission (e.g. hepatitis, HIV, West Nile
virus). Fibrogammin P is highly purified and heat-
treated to minimize such risks.
The data from this small sample of subjects
indicate a clinically significant reduction in sponta-
neous bleeding episodes among subjects receiving
Fibrogammin P for routine prophylaxis. These
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recent data from the United States support previously
published data from Europe and should be of interest
to the readers of Haemophilia. This information is
important to those involved in the management of
patients with this rare and serious bleeding disorder.
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